in 2018 3 Settings for Initiating Aspirin Serious Vascular Events in Primary Prevention Trials USPSTF Analysis USPSTF 2016 Statement of Aspirin Use Contemporary Clinical Trials Exploring the Role of Aspirin for Cardioprevention ID: 775085
Download Presentation The PPT/PDF document " Aspirin and Cardioprevention " is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Aspirin and Cardioprevention in 2018
Slide23 Settings for Initiating Aspirin
Slide3Serious Vascular Events in Primary Prevention Trials
Slide4USPSTF Analysis
Slide5USPSTF 2016 Statement of Aspirin Use
Slide6Contemporary Clinical Trials Exploring the Role of Aspirin for Cardioprevention
Slide7Patient Case 1
Slide8When to Consider Aspirin?
Slide9Aspirin for Secondary Prevention
Slide10Patient Case 2
Slide11Approach to Considering Aspirin Use for Primary Prevention
Slide12Patient Case 2
Slide13ARRIVEStudy Design
Slide14ARRIVEBaseline Characteristics
Slide15ARRIVEResults
Slide16ARRIVE: Components of Primary Endpoint Cumulative Incidence
Slide17ARRIVEResults
Slide18ARRIVE Interpreting the Results
Slide19Primary Prevention Trials With Aspirin in Patients With Diabetes
Slide20ASCEND Study Design
Slide21ASCEND Aspirin Effect on Vascular and Bleeding Outcomes
Slide22Aspirin Recommendations for Patients With Diabetes
Slide23ASPREE Study Design
Slide24ASPREE Results
Slide25ASPREEResults (cont)
Slide26Risk Factors for GI Bleeding with Aspirin
Slide27Conclusion
Slide28Abbreviations
Slide29Abbreviations (cont)